Blockade of PD‐1 or p38 MAP kinase signaling enhances senescent human CD8+ T‐cell proliferation by distinct pathways
Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T‐cell subset that re‐expresses CD45RA (EMRA)...
Saved in:
Published in | European journal of immunology Vol. 45; no. 5; pp. 1441 - 1451 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
01.05.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T‐cell subset that re‐expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD‐1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T cells was only enhanced by blocking the p38 but not the PD‐1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF‐α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD‐1 signaling in these cells. Therefore, end‐stage characteristics of EMRA CD8+ T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD‐1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8+ T cells without compromising their capacity for cytokine secretion. |
---|---|
AbstractList | Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8(+) T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD-1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8(+) T cells was only enhanced by blocking the p38 but not the PD-1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF-α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD-1 signaling in these cells. Therefore, end-stage characteristics of EMRA CD8(+) T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD-1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8(+) T cells without compromising their capacity for cytokine secretion.Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8(+) T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD-1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8(+) T cells was only enhanced by blocking the p38 but not the PD-1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF-α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD-1 signaling in these cells. Therefore, end-stage characteristics of EMRA CD8(+) T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD-1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8(+) T cells without compromising their capacity for cytokine secretion. Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T‐cell subset that re‐expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD‐1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T cells was only enhanced by blocking the p38 but not the PD‐1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF‐α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD‐1 signaling in these cells. Therefore, end‐stage characteristics of EMRA CD8+ T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD‐1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8+ T cells without compromising their capacity for cytokine secretion. Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein [gamma]H2AX. Blocking of both PD-1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T cells was only enhanced by blocking the p38 but not the PD-1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF-[alpha] secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD-1 signaling in these cells. Therefore, end-stage characteristics of EMRA CD8+ T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD-1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8+ T cells without compromising their capacity for cytokine secretion. Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8 + T‐cell subset that re‐expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD‐1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8 + T cells was only enhanced by blocking the p38 but not the PD‐1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF‐α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD‐1 signaling in these cells. Therefore, end‐stage characteristics of EMRA CD8 + T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD‐1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8 + T cells without compromising their capacity for cytokine secretion. |
Author | Macaulay, Richard Nunn, Craig J. Riddell, Natalie E. Henson, Sian M. Akbar, Arne N. |
Author_xml | – sequence: 1 givenname: Sian M. surname: Henson fullname: Henson, Sian M. organization: University College London – sequence: 2 givenname: Richard surname: Macaulay fullname: Macaulay, Richard organization: University College London – sequence: 3 givenname: Natalie E. surname: Riddell fullname: Riddell, Natalie E. organization: University College London – sequence: 4 givenname: Craig J. surname: Nunn fullname: Nunn, Craig J. organization: University College London – sequence: 5 givenname: Arne N. surname: Akbar fullname: Akbar, Arne N. organization: University College London |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25707450$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc9u1DAQxi1URLeFI1dkiQsSSuvxnyQ-lm2Bolb0UM6R40y63mbtrZ2o7I1H4Bl5Erxs6aESnMYa_z7P5_kOyJ4PHgl5DewIGOPHuHRHnIGUSgB_RmagOBQSJOyRGcv9guua7ZODlJaMMV0q_YLsc1WxSio2I98_DMHemg5p6OnV6a8fP4GGSNeippcnV_TWeZOQJnfjzeD8DUW_MN5iogk9Jot-pItpZTydn9bv6XXWWxwGuo5hcD1GM7rgabuhnUuj83akazMu7s0mvSTPezMkfPVQD8m3j2fX88_FxddP5_OTi8JKJnghlK2FFLrECk1XydJ2Nh9lr9oWWqhUq4RmpUZha2ulzjeItgMOfVebvheH5N3u3WzpbsI0NiuXth6NxzClBsqaQVUKrTL69gm6DFPMH99SleYcdCkz9eaBmtoVds06upWJm-bvTjNQ7AAbQ0oR-0cEWLPNrMmZNY-ZZV484a0b_yxujMYN_1TxnereDbj5_4jm7Mu54JqL322Pqhs |
CODEN | EJIMAF |
CitedBy_id | crossref_primary_10_3390_ijms23137358 crossref_primary_10_3389_fimmu_2021_632667 crossref_primary_10_3390_ijms23179797 crossref_primary_10_2174_1381612825666190313115233 crossref_primary_10_3389_fimmu_2022_833531 crossref_primary_10_1016_j_ebiom_2021_103409 crossref_primary_10_1038_cmi_2017_111 crossref_primary_10_1016_j_immuni_2017_03_010 crossref_primary_10_1111_cei_12829 crossref_primary_10_3389_fimmu_2020_604591 crossref_primary_10_3389_fimmu_2018_03001 crossref_primary_10_1016_j_ctarc_2021_100494 crossref_primary_10_1016_j_celrep_2018_05_057 crossref_primary_10_1016_j_jgo_2017_02_001 crossref_primary_10_1186_s13018_025_05473_0 crossref_primary_10_1002_cti2_1091 crossref_primary_10_1002_jcp_26956 crossref_primary_10_1111_cei_13189 crossref_primary_10_3389_fimmu_2022_1046755 crossref_primary_10_1111_cei_13344 crossref_primary_10_1016_j_semcancer_2024_11_003 crossref_primary_10_3389_fcell_2021_694831 crossref_primary_10_3390_ijms20092258 crossref_primary_10_1016_j_isci_2023_108746 crossref_primary_10_3390_ijms22137016 crossref_primary_10_1016_j_exger_2017_07_002 crossref_primary_10_3389_fimmu_2017_00692 crossref_primary_10_1080_15412555_2023_2299104 crossref_primary_10_1038_s41577_019_0180_1 crossref_primary_10_1158_1078_0432_CCR_20_1420 crossref_primary_10_3389_fimmu_2023_1284293 crossref_primary_10_1083_jcb_202401112 crossref_primary_10_1016_j_clim_2022_109202 crossref_primary_10_1016_j_it_2016_09_002 crossref_primary_10_3389_fonc_2020_01671 crossref_primary_10_3390_vaccines9121392 crossref_primary_10_3390_vaccines5010005 crossref_primary_10_3390_cells10092435 crossref_primary_10_3389_fimmu_2016_00616 crossref_primary_10_1016_j_intimp_2024_111807 crossref_primary_10_1016_j_exger_2016_12_001 crossref_primary_10_3389_fimmu_2023_1233870 crossref_primary_10_1111_acel_13272 crossref_primary_10_1186_s12979_023_00394_0 crossref_primary_10_3390_ijms21124346 crossref_primary_10_1016_j_brainresbull_2024_111055 crossref_primary_10_1007_s11912_017_0619_0 crossref_primary_10_1111_cei_12836 crossref_primary_10_3389_fimmu_2025_1487318 crossref_primary_10_1684_ecn_2020_0441 crossref_primary_10_3389_fragi_2024_1436346 crossref_primary_10_1016_j_clim_2021_108685 crossref_primary_10_1016_j_it_2023_05_005 crossref_primary_10_3390_ijms252312550 crossref_primary_10_1016_j_lungcan_2024_107925 crossref_primary_10_1097_QAD_0000000000001441 crossref_primary_10_3390_cancers14041078 crossref_primary_10_1111_acel_13028 crossref_primary_10_3389_fimmu_2024_1338680 crossref_primary_10_3390_cancers15071927 crossref_primary_10_3389_fimmu_2023_1212100 crossref_primary_10_3389_fimmu_2018_00339 crossref_primary_10_1038_leu_2016_84 crossref_primary_10_3389_fimmu_2022_906355 crossref_primary_10_1371_journal_pone_0280851 crossref_primary_10_1172_jci_insight_120974 crossref_primary_10_18632_aging_205985 crossref_primary_10_1016_j_isci_2022_104202 crossref_primary_10_1016_j_semcancer_2024_12_001 crossref_primary_10_3389_fimmu_2020_583019 crossref_primary_10_1016_j_ccell_2020_05_004 crossref_primary_10_1038_s41598_024_80971_5 crossref_primary_10_3389_fimmu_2017_00778 crossref_primary_10_1002_eji_201546178 crossref_primary_10_1007_s00262_016_1803_z crossref_primary_10_14336_AD_2024_0219 crossref_primary_10_1038_s41573_024_01126_9 crossref_primary_10_70401_acrt_2024_104 crossref_primary_10_1002_JLB_5MR0520_466R crossref_primary_10_3390_biom13071085 crossref_primary_10_1016_j_critrevonc_2020_103036 crossref_primary_10_1016_j_arr_2022_101634 crossref_primary_10_1111_acel_12675 crossref_primary_10_1042_BST20150092 crossref_primary_10_1016_j_prp_2024_155534 crossref_primary_10_1016_j_exger_2018_01_005 crossref_primary_10_1016_j_esmoop_2022_100577 crossref_primary_10_31491_APT_2022_06_083 crossref_primary_10_1016_j_ejca_2021_11_024 crossref_primary_10_1111_acel_14300 crossref_primary_10_1186_s40425_018_0336_8 crossref_primary_10_1038_s41577_020_00454_2 crossref_primary_10_1189_jlb_3MA0717_283 crossref_primary_10_1007_s10522_023_10075_6 crossref_primary_10_1111_cei_12876 crossref_primary_10_1007_s10522_018_9771_7 crossref_primary_10_1002_mco2_70048 crossref_primary_10_3389_fimmu_2024_1360141 crossref_primary_10_1002_ijc_31813 crossref_primary_10_3389_fragi_2023_1202152 crossref_primary_10_1111_acel_14317 crossref_primary_10_1111_imr_13206 crossref_primary_10_3389_fragi_2021_719342 crossref_primary_10_3389_fimmu_2017_01960 |
Cites_doi | 10.1084/jem.20100637 10.1038/nri2959 10.4049/jimmunol.1203267 10.1084/jem.194.12.1711 10.1016/j.virol.2004.11.028 10.1038/nature02118 10.1093/intimm/dxn123 10.1182/blood-2006-06-027060 10.1182/blood-2009-01-199588 10.1038/ni.1679 10.1128/JVI.77.8.4911-4927.2003 10.4049/jimmunol.175.12.8218 10.1038/nri2318 10.1073/pnas.0503095102 10.1038/nm0402-379 10.1016/S1097-2765(04)00256-4 10.1186/ar1905 10.1016/j.it.2009.03.013 10.1016/j.critrevonc.2013.08.002 10.1111/j.1365-2567.2010.03386.x 10.1007/s10875-010-9499-x 10.1111/j.1365-2567.2010.03345.x 10.1111/imm.12409 10.1016/S0264-410X(99)00502-2 10.4049/jimmunol.1301409 10.1016/j.cell.2012.01.003 10.1038/nature05115 10.1016/j.immuni.2007.09.006 10.1111/j.1365-2567.2011.03550.x 10.1038/nri1440 10.4049/jimmunol.178.12.7710 10.1242/jcs.019372 10.1186/1742-4933-5-6 10.1172/JCI75051 10.1038/ni1515 10.4049/jimmunol.175.12.8003 10.1084/jem.20072076 10.1111/j.1600-065X.2009.00767.x 10.1084/jem.20100643 10.1046/j.1365-2443.2003.00620.x 10.4049/jimmunol.0901522 10.1177/0091270009357433 10.1038/nri1254 10.1002/art.24266 10.1002/cyto.a.20643 10.1002/cyto.a.21015 10.1016/j.ejpain.2011.04.005 10.1111/j.1432-2277.2009.00927.x 10.4049/jimmunol.1100978 |
ContentType | Journal Article |
Copyright | 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim |
Copyright_xml | – notice: 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim – notice: 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. – notice: 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TK 7TM 8FD FR3 H94 K9. M7N P64 RC3 7X8 |
DOI | 10.1002/eji.201445312 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database Algology Mycology and Protozoology Abstracts (Microbiology C) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Genetics Abstracts CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1521-4141 |
EndPage | 1451 |
ExternalDocumentID | 3677076741 25707450 10_1002_eji_201445312 EJI3292 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Biotechnology and Biological Sciences Research Council – fundername: Medical Research Council grantid: MR/M003833/1 – fundername: Biotechnology and Biological Sciences Research Council grantid: BB/E019188/1 – fundername: Biotechnology and Biological Sciences Research Council grantid: BB/J006750/1 |
GroupedDBID | --- .3N .55 .GA .GJ .HR .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEFU ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M J5H JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 TEORI UB1 UPT V2E VH1 W8V W99 WBKPD WHWMO WIB WIH WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXSBR X7M XG1 XPP XV2 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7QP 7T5 7TK 7TM 8FD FR3 H94 K9. M7N P64 RC3 7X8 |
ID | FETCH-LOGICAL-c4032-35c834396e7ead746cdce7e4f5bb1b175b539069e3c8cc49e4feecd121fd8aff3 |
IEDL.DBID | DR2 |
ISSN | 0014-2980 1521-4141 |
IngestDate | Fri Jul 11 05:12:08 EDT 2025 Fri Jul 25 12:11:34 EDT 2025 Mon Jul 21 05:56:59 EDT 2025 Tue Jul 01 01:05:33 EDT 2025 Thu Apr 24 23:00:30 EDT 2025 Wed Jan 22 16:21:01 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Inhibitory receptors Aging T cells |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4032-35c834396e7ead746cdce7e4f5bb1b175b539069e3c8cc49e4feecd121fd8aff3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eji.201445312 |
PMID | 25707450 |
PQID | 1679221964 |
PQPubID | 986365 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1680176395 proquest_journals_1679221964 pubmed_primary_25707450 crossref_primary_10_1002_eji_201445312 crossref_citationtrail_10_1002_eji_201445312 wiley_primary_10_1002_eji_201445312_EJI3292 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | May 2015 2015-05-00 2015-May 20150501 |
PublicationDateYYYYMMDD | 2015-05-01 |
PublicationDate_xml | – month: 05 year: 2015 text: May 2015 |
PublicationDecade | 2010 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim |
PublicationTitle | European journal of immunology |
PublicationTitleAlternate | Eur J Immunol |
PublicationYear | 2015 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2005; 175 2005; 332 2004; 4 2011; 11 2008; 8 2009; 113 2008; 5 2011; 15 2008; 73 2007; 109 2007; 178 2000; 18 2009; 10 1989; 75 2012; 135 2005; 102 2003; 8 2007; 8 2003; 3 2013; 191 2013; 190 2014; 124 2006; 443 2007; 27 2009; 22 2009; 21 2010; 207 2009; 60 2002; 8 2011; 31 2006; 8 2008; 205 2011; 79 2012; 148 2008; 121 2014; 89 2011; 132 2003; 77 2009; 30 2003; 426 2001; 194 2002; 62 2004; 14 2010; 132 2009; 183 2014; 144 2009; 229 2011; 187 2010; 50 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_49_1 e_1_2_7_28_1 e_1_2_7_50_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_37_1 e_1_2_7_39_1 e_1_2_7_6_1 e_1_2_7_4_1 Valmori D. (e_1_2_7_5_1) 2002; 62 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_12_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_48_1 e_1_2_7_27_1 e_1_2_7_29_1 Monteiro M. (e_1_2_7_17_1) 2007; 109 e_1_2_7_51_1 e_1_2_7_30_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_38_1 Nagel J. E. (e_1_2_7_44_1) 1989; 75 |
References_xml | – volume: 4 start-page: 737 year: 2004 end-page: 743 article-title: Will telomere erosion lead to a loss of T‐cell memory? publication-title: Nat. Rev. Immunol. – volume: 175 start-page: 8218 year: 2005 end-page: 8225 article-title: Cytomegalovirus‐specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion publication-title: J. Immunol. – volume: 229 start-page: 114 year: 2009 end-page: 125 article-title: PD‐1 signaling in primary T cells publication-title: Immunol. Rev. – volume: 426 start-page: 194 year: 2003 end-page: 198 article-title: A DNA damage checkpoint response in telomere‐initiated senescence publication-title: Nature – volume: 178 start-page: 7710 year: 2007 end-page: 7719 article-title: The loss of telomerase activity in highly differentiated CD8+CD28‐CD27‐ T cells is associated with decreased Akt (Ser473) phosphorylation publication-title: J. Immunol. – volume: 194 start-page: 1711 year: 2001 end-page: 1719 article-title: Cytokine‐driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells publication-title: J. Exp. Med. – volume: 73 start-page: 975 year: 2008 end-page: 983 article-title: Phenotype and function of human T lymphocyte subsets: consensus and issues publication-title: Cytometry A – volume: 121 start-page: 1046 year: 2008 end-page: 1053 article-title: Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress publication-title: J. Cell Sci. – volume: 60 start-page: 335 year: 2009 end-page: 344 article-title: Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritis publication-title: Arthritis Rheum. – volume: 205 start-page: 2111 year: 2008 end-page: 2124 article-title: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection publication-title: J. Exp. Med. – volume: 135 start-page: 355 year: 2012 end-page: 363 article-title: Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade publication-title: Immunology – volume: 191 start-page: 3744 year: 2013 end-page: 3752 article-title: IFN‐alpha inhibits telomerase in human CD8(+) T cells by both hTERT downregulation and induction of p38 MAPK signaling publication-title: J. Immunol. – volume: 11 start-page: 289 year: 2011 end-page: 295 article-title: Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? publication-title: Nat. Rev. Immunol. – volume: 144 start-page: 549 year: 2014 end-page: 560 article-title: Multifunctional cytomegalovirus (CMV)‐specific CD8 T cells are not restricted by telomere‐related senescence in young or old adults publication-title: Immunology – volume: 175 start-page: 8003 year: 2005 end-page: 8010 article-title: IL‐2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation publication-title: J. Immunol. – volume: 30 start-page: 306 year: 2009 end-page: 312 article-title: CD28(‐) T cells: their role in the age‐associated decline of immune function publication-title: Trends Immunol. – volume: 10 start-page: 29 year: 2009 end-page: 37 article-title: Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection publication-title: Nat. Immunol. – volume: 8 start-page: 512 year: 2008 end-page: 522 article-title: Ageing and life‐long maintenance of T‐cell subsets in the face of latent persistent infections publication-title: Nat. Rev. Immunol. – volume: 207 start-page: 2187 year: 2010 end-page: 2194 article-title: Targeting Tim‐3 and PD‐1 pathways to reverse T cell exhaustion and restore anti‐tumor immunity publication-title: J. Exp. Med. – volume: 27 start-page: 670 year: 2007 end-page: 684 article-title: Molecular signature of CD8+ T cell exhaustion during chronic viral infection publication-title: Immunity – volume: 8 start-page: 131 year: 2003 end-page: 144 article-title: Mitogen‐activated protein kinase p38 defines the common senescence‐signalling pathway publication-title: Genes Cells – volume: 183 start-page: 7063 year: 2009 end-page: 7072 article-title: Interplay between chromatin remodeling and epigenetic changes during lineage‐specific commitment to granzyme B expression publication-title: J. Immunol. – volume: 21 start-page: 53 year: 2009 end-page: 62 article-title: Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART‐1‐specific CD8+ T cells publication-title: Int. Immunol. – volume: 132 start-page: 104 year: 2010 end-page: 110 article-title: Activation of p38 mitogen‐activated protein kinase is critical step for acquisition of effector function in cytokine‐activated T cells, but acts as a negative regulator in T cells activated through the T‐cell receptor publication-title: Immunology – volume: 79 start-page: 167 year: 2011 end-page: 174 article-title: SPICE: exploration and analysis of post‐cytometric complex multivariate datasets publication-title: Cytometry A – volume: 8 start-page: 1246 year: 2007 end-page: 1254 article-title: Upregulation of CTLA‐4 by HIV‐specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction publication-title: Nat. Immunol. – volume: 50 start-page: 1031 year: 2010 end-page: 1038 article-title: A proof‐of‐concept and drug‐drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis publication-title: J. Clin. Pharmacol. – volume: 332 start-page: 16 year: 2005 end-page: 19 article-title: Decreased perforin and granzyme B expression in senescent HIV‐1‐specific cytotoxic T lymphocytes publication-title: Virology – volume: 22 start-page: 1041 year: 2009 end-page: 1050 article-title: The aging of the immune system publication-title: Transpl. Int. – volume: 132 start-page: 326 year: 2011 end-page: 339 article-title: Cytomegalovirus infection induces the accumulation of short‐lived, multifunctional CD4+CD45RA+CD27+ T cells: the potential involvement of interleukin‐7 in this process publication-title: Immunology – volume: 14 start-page: 501 year: 2004 end-page: 513 article-title: Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a) publication-title: Mol. Cell – volume: 443 start-page: 350 year: 2006 end-page: 354 article-title: PD‐1 expression on HIV‐specific T cells is associated with T‐cell exhaustion and disease progression publication-title: Nature – volume: 113 start-page: 6619 year: 2009 end-page: 6628 article-title: KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells publication-title: Blood – volume: 31 start-page: 137 year: 2011 end-page: 146 article-title: Gain and loss of T cell subsets in old age—age‐related reshaping of the T cell repertoire publication-title: J. Clin. Immunol. – volume: 102 start-page: 8222 year: 2005 end-page: 8227 article-title: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses publication-title: Proc. Natl. Acad. Sci. USA – volume: 207 start-page: 2175 year: 2010 end-page: 2186 article-title: Upregulation of Tim‐3 and PD‐1 expression is associated with tumor antigen‐specific CD8+ T cell dysfunction in melanoma patients publication-title: J. Exp. Med. – volume: 190 start-page: 5363 year: 2013 end-page: 5372 article-title: Age‐associated increase of low‐avidity cytomegalovirus‐specific CD8+ T cells that re‐express CD45RA publication-title: J. Immunol. – volume: 148 start-page: 46 year: 2012 end-page: 57 article-title: Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock publication-title: Cell – volume: 75 start-page: 286 year: 1989 end-page: 291 article-title: Effect of age on the human high affinity interleukin 2 receptor of phytohaemagglutinin stimulated peripheral blood lymphocytes publication-title: Clin. Exp. Immunol. – volume: 8 start-page: 205 year: 2006 article-title: The p38 mitogen‐activated protein kinase signaling cascade in CD4 T cells publication-title: Arthritis Res. Ther. – volume: 5 start-page: 6 year: 2008 article-title: Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people publication-title: Immun. Ageing – volume: 124 start-page: 4004 year: 2014 end-page: 4016 article-title: p38 signaling inhibits mTORC1‐independent autophagy in senescent human CD8+ T cells publication-title: J. Clin. Invest. – volume: 62 start-page: 1743 year: 2002 end-page: 1750 article-title: Circulating tumor‐reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(‐) effector subset exerting ex vivo tumor‐specific cytolytic activity publication-title: Cancer Res. – volume: 15 start-page: 1040 year: 2011 end-page: 1048 article-title: Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury publication-title: Eur. J. Pain – volume: 3 start-page: 931 year: 2003 end-page: 939 article-title: Human CD8(+) T‐cell differentiation in response to viruses publication-title: Nat. Rev. Immunol. – volume: 8 start-page: 379 year: 2002 end-page: 385 article-title: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections publication-title: Nat. Med. – volume: 77 start-page: 4911 year: 2003 end-page: 4927 article-title: Viral persistence alters CD8 T‐cell immunodominance and tissue distribution and results in distinct stages of functional impairment publication-title: J. Virol. – volume: 18 start-page: 1654 year: 2000 end-page: 1660 article-title: Effect of aging on T lymphocyte activation publication-title: Vaccine – volume: 187 start-page: 2093 year: 2011 end-page: 2100 article-title: Reversible senescence in human CD4+CD45RA+CD27‐ memory T cells publication-title: J. Immunol. – volume: 89 start-page: 140 year: 2014 end-page: 165 article-title: Targeting the PD1/PD‐L1 axis in melanoma: biological rationale, clinical challenges and opportunities publication-title: Crit. Rev. Oncol. Hematol. – volume: 109 start-page: 2863 year: 2007 end-page: 2870 article-title: Cartography of gene expression in CD8 single cells: novel CCR7‐subsets suggest differentiation independent of CD45RA expression publication-title: Blood – ident: e_1_2_7_20_1 doi: 10.1084/jem.20100637 – ident: e_1_2_7_15_1 doi: 10.1038/nri2959 – ident: e_1_2_7_24_1 doi: 10.4049/jimmunol.1203267 – ident: e_1_2_7_41_1 doi: 10.1084/jem.194.12.1711 – ident: e_1_2_7_42_1 doi: 10.1016/j.virol.2004.11.028 – ident: e_1_2_7_22_1 doi: 10.1038/nature02118 – ident: e_1_2_7_12_1 doi: 10.1093/intimm/dxn123 – volume: 109 start-page: 2863 year: 2007 ident: e_1_2_7_17_1 article-title: Cartography of gene expression in CD8 single cells: novel CCR7‐subsets suggest differentiation independent of CD45RA expression publication-title: Blood doi: 10.1182/blood-2006-06-027060 – ident: e_1_2_7_51_1 doi: 10.1182/blood-2009-01-199588 – ident: e_1_2_7_26_1 doi: 10.1038/ni.1679 – ident: e_1_2_7_30_1 doi: 10.1128/JVI.77.8.4911-4927.2003 – ident: e_1_2_7_18_1 doi: 10.4049/jimmunol.175.12.8218 – ident: e_1_2_7_3_1 doi: 10.1038/nri2318 – ident: e_1_2_7_38_1 doi: 10.1073/pnas.0503095102 – ident: e_1_2_7_40_1 doi: 10.1038/nm0402-379 – ident: e_1_2_7_23_1 doi: 10.1016/S1097-2765(04)00256-4 – ident: e_1_2_7_39_1 doi: 10.1186/ar1905 – ident: e_1_2_7_14_1 doi: 10.1016/j.it.2009.03.013 – ident: e_1_2_7_31_1 doi: 10.1016/j.critrevonc.2013.08.002 – ident: e_1_2_7_8_1 doi: 10.1111/j.1365-2567.2010.03386.x – ident: e_1_2_7_11_1 doi: 10.1007/s10875-010-9499-x – ident: e_1_2_7_29_1 doi: 10.1111/j.1365-2567.2010.03345.x – ident: e_1_2_7_25_1 doi: 10.1111/imm.12409 – ident: e_1_2_7_43_1 doi: 10.1016/S0264-410X(99)00502-2 – ident: e_1_2_7_28_1 doi: 10.4049/jimmunol.1301409 – ident: e_1_2_7_48_1 doi: 10.1016/j.cell.2012.01.003 – ident: e_1_2_7_19_1 doi: 10.1038/nature05115 – ident: e_1_2_7_49_1 doi: 10.1016/j.immuni.2007.09.006 – ident: e_1_2_7_50_1 doi: 10.1111/j.1365-2567.2011.03550.x – ident: e_1_2_7_2_1 doi: 10.1038/nri1440 – ident: e_1_2_7_10_1 doi: 10.4049/jimmunol.178.12.7710 – ident: e_1_2_7_37_1 doi: 10.1242/jcs.019372 – ident: e_1_2_7_16_1 doi: 10.1186/1742-4933-5-6 – ident: e_1_2_7_9_1 doi: 10.1172/JCI75051 – ident: e_1_2_7_32_1 doi: 10.1038/ni1515 – ident: e_1_2_7_46_1 doi: 10.4049/jimmunol.175.12.8003 – ident: e_1_2_7_7_1 doi: 10.1084/jem.20072076 – volume: 75 start-page: 286 year: 1989 ident: e_1_2_7_44_1 article-title: Effect of age on the human high affinity interleukin 2 receptor of phytohaemagglutinin stimulated peripheral blood lymphocytes publication-title: Clin. Exp. Immunol. – ident: e_1_2_7_36_1 doi: 10.1111/j.1600-065X.2009.00767.x – ident: e_1_2_7_21_1 doi: 10.1084/jem.20100643 – volume: 62 start-page: 1743 year: 2002 ident: e_1_2_7_5_1 article-title: Circulating tumor‐reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(‐) effector subset exerting ex vivo tumor‐specific cytolytic activity publication-title: Cancer Res. – ident: e_1_2_7_27_1 doi: 10.1046/j.1365-2443.2003.00620.x – ident: e_1_2_7_47_1 doi: 10.4049/jimmunol.0901522 – ident: e_1_2_7_33_1 doi: 10.1177/0091270009357433 – ident: e_1_2_7_6_1 doi: 10.1038/nri1254 – ident: e_1_2_7_35_1 doi: 10.1002/art.24266 – ident: e_1_2_7_4_1 doi: 10.1002/cyto.a.20643 – ident: e_1_2_7_52_1 doi: 10.1002/cyto.a.21015 – ident: e_1_2_7_34_1 doi: 10.1016/j.ejpain.2011.04.005 – ident: e_1_2_7_45_1 doi: 10.1111/j.1432-2277.2009.00927.x – ident: e_1_2_7_13_1 doi: 10.4049/jimmunol.1100978 |
SSID | ssj0009659 |
Score | 2.4838157 |
Snippet | Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1441 |
SubjectTerms | Adult Aged Aged, 80 and over Aging Aging - immunology Aging - pathology CD8-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Cell Differentiation - immunology Cell Proliferation Cellular Senescence - immunology Cytokines - metabolism Histones - metabolism Humans Immunologic Memory Inhibitory receptors Kinases Leukocyte Common Antigens - metabolism Lymphocytes MAP Kinase Signaling System p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors p38 Mitogen-Activated Protein Kinases - immunology Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology T cells T-Lymphocyte Subsets - cytology T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism Telomerase Telomerase - metabolism Young Adult |
Title | Blockade of PD‐1 or p38 MAP kinase signaling enhances senescent human CD8+ T‐cell proliferation by distinct pathways |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Feji.201445312 https://www.ncbi.nlm.nih.gov/pubmed/25707450 https://www.proquest.com/docview/1679221964 https://www.proquest.com/docview/1680176395 |
Volume | 45 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9RAFB6koPhitd5Sq4wgvtS0ycxkkjzWXqiFlSIt9C3O5QTrSnZpdtH1yZ_gb_SXeE4mm7KKgvgWMmdIMjm3mTnzfYy90A6DsCxMnECqYuXRD5a1S2OdC2tAq7x0tDQwequPz9XJRXbR85zSWZiADzEsuJFldP6aDNzYdvcaNBQ-XlJlllKoReSDqV6LkqJ31_BRBJYXPLGKRVkkPcYm9t9d6b0ak35LNFfz1i7wHK2z98tXDvUm4535zO64r7-gOf7HN91ld_qklO8FLbrHbkCzwW4GmsrFBrs16jfg77MvrzH4jY0HPqn56cGPb99TPrniU1nw0d4pH182GBU5FYUYOufOoflAatXylnwqVYLyjhWQ7x8U2_wM-9POAZ8Sd1ANQRu5XXBPrqdxM06MyZ_Non3Azo8Oz_aP4568IXYqkXRCwBUSsx0NOSprrrTzDi9VnVmbWkxabCbLRJcgXeGcKrEFwPlUpLUvTF3Lh2ytmTTwmHGXK4MzeADQoEqtClBS47zXgPc-E3nEXi1_X-V6ZHMi2PhUBUxmUeG4VsO4RuzlID4NkB5_Etxa6kLVW3Zb0baVEARjFrHnQzPaJA2XaWAyJxmM--i4yyxij4IODU8i1sBcZUnEtjtN-PsrVIcnb6QoxeY_ST9ht_FeFuoyt9ja7GoOTzF3mtlnnYH8BGZ3EVk |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwEB6hIo4XjnIFChgJ8VLSJo7jJI-lh7alW1VoK_UtcpyJaLfKrrq7guWJn8Bv5JcwE2dTFgQS4i2SxzmcuWyPvw_gtbYUhKPU-AGGylcl-cGssqGvE1kY1CrJLC8N9I9070QdnManP53id_gQ3YIbW0bjr9nAeUF68wo1FM_PuDRLKVIjcsLXmdW7mVR9uAKQYrg854uVL7M0aFE26QabS92Xo9JvqeZy5tqEnr27YBYv7SpOhhuzabFhv_yC5_g_X3UP7rR5qdhyinQfrmG9CjccU-V8FW722z34B_D5HcW_oSlRjCpxvPP967dQjC7FOEpFf-tYDM9qCoyC60IMH3UXWH9kzZqICbtVLgYVDTGg2N5J18WA-vPmgRgzfVCFTiFFMRcle5_aTgWTJn8y88lDONnbHWz3_Ja_wbcqiPiQgE0jSng0JqSvidK2tHSpqrgowoLyliKOskBnGNnUWpVRC6ItQxlWZWqqKnoEK_WoxicgbKIMTeIRUaPKtEpRRZqmvgbLsoxl4sHbxf_LbQtuzhwbF7mDZZY5jWvejasHbzrxsUP1-JPg2kIZ8ta4JznvXEnJSGYevOqaySx5uEyNoxnLUOgn353FHjx2StQ9iYkDExUHHqw3qvD3V8h3D_Yjmcmn_yT9Em71Bv3D_HD_6P0zuE3tsSvTXIOV6eUMn1MqNS1eNNbyA3I8FXQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6hIiouPAqUQAEjIS4lbR6O4xxLt6u2sNUKtVJvIbEnoizKrrq7guXET-A38kuYibOpFgQS4hbJ4zycbx62x98AvFCGnHCsCz_AUPrSkh3MKhP6Ko3KApVMM8NLA4MTdXgmj8-T87bOKZ-FcfwQ3YIba0Zjr1nBJ7bavSINxY8XnJklJaGIbPB1qQLNsO69u-KPYrY8Z4qlH2U6aEk26Qa7K91XndJvkeZq4Np4nv5teL98Z5dwMtqZz8od8_UXOsf_-Kg7cKuNSsWeg9FduIb1BtxwdSoXG7A-aHfg78GX1-T9RoVFMa7EsPfj2_dQjC_FJNZisDcUo4ua3KLgrJCCD7oLrD8wrqZiykaVU0FFUxZQ7Pf0tjil_rx1ICZcPKhCB0dRLoRl21ObmeCSyZ-LxfQ-nPUPTvcP_bZ6g29kEPMRAaNjCncUpoTWVCpjDV3KKinLsKSopUziLFAZxkYbIzNqQTQ2jMLK6qKq4gewVo9rfAjCpLKgKTwiKpSZkhplrGjiW6C1NolSD14tf19uWmpzrrDxKXekzFFO45p34-rBy0584jg9_iS4tcRC3qr2NOd9qyhiHjMPnnfNpJQ8XEWN4znLkOMny50lHmw6DHVP4rKBqUwCD7YbJPz9FfKD46M4yqJH_yT9DNaHvX7-9ujkzWO4Sc2Jy9HcgrXZ5RyfUBw1K582uvITOtQULA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Blockade+of+PD%E2%80%901+or+p38+MAP+kinase+signaling+enhances+senescent+human+CD8+%2B+T%E2%80%90cell+proliferation+by+distinct+pathways&rft.jtitle=European+journal+of+immunology&rft.au=Henson%2C+Sian+M.&rft.au=Macaulay%2C+Richard&rft.au=Riddell%2C+Natalie+E.&rft.au=Nunn%2C+Craig+J.&rft.date=2015-05-01&rft.issn=0014-2980&rft.eissn=1521-4141&rft.volume=45&rft.issue=5&rft.spage=1441&rft.epage=1451&rft_id=info:doi/10.1002%2Feji.201445312&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_eji_201445312 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2980&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2980&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2980&client=summon |